Table 1.
Outcomes | Two-group (no vs any muscle-strengthening activities) meta-analysis | Dose–response meta-analysis (10 min/week increase) | |||||||||
N | Cases/participants | RR (95% CI) | P value | I2, p value | N | Cases/participants | RR (95% CI) | P value | I2, p value | GRADE* | |
All-cause mortality | 7 | 42 133/263 058 | 0.85 (0.79 to 0.93) | <0.001 | 83%,<0.001 | 6 | 37 178/236 331 | 0.99 (0.98 to 1.00)† | 0.05 | 75%, 0.001 | ⨁◯◯◯ |
CVD | 7 | 16 056/257 888 | 0.83 (0.73 to 0.93) | 0.002 | 73%,<0.001 | 5 | 11 263/226 746 | 0.996 (0.99 to 1.003)‡ | 0.26 | 0%, 0.46 | ⨁◯◯◯ |
Total cancer | 6 | 21 253/540 543 | 0.88 (0.80 to 0.97) | 0.008 | 76%,<0.001 | 4 | 13 033/212 323 | 0.99 (0.98 to 1.004)§ | 0.15 | 80%, 0.002 | ⨁◯◯◯ |
Diabetes | 5 | 9548/202 486 | 0.83 (0.77 to 0.89) | <0.001 | 36%, 0.18 | 3 | 7511/167 072 | 0.98 (0.97 to 0.99)¶ | 0.003 | 59%, 0.09 | ⨁⨁◯◯ |
Colon cancer | 2 | 2415/248 909 | 0.96 (0.91 to 1.01) | 0.09 | 0%,<0.35 | 2 | 2415/248 909 | 0.998 (0.96 to 1.04) | 0.91 | 94%,<0.001 | ⨁◯◯◯ |
Kidney cancer | 2 | 1063/248 909 | 0.88 (0.76 to 1.02) | 0.08 | 0%,<0.52 | 2 | 1063/248 909 | 0.98 (0.96 to 1.002) | 0.08 | 9%, 0.29 | ⨁◯◯◯ |
Bladder cancer | 2 | 2341/248 909 | 0.94 (0.84 to 1.05) | 0.27 | 19%,<0.27 | 2 | 2341/248 909 | 0.98 (0.95 to 1.02) | 0.34 | 77%, 0.04 | ⨁◯◯◯ |
Lung cancer | 2 | 4075/248 909 | 0.90 (0.83 to 0.98) | 0.01 | 0%,<0.69 | 2 | 4075/248 909 | 0.99 (0.98 to 1.00) | 0.045 | 0%, 0.81 | ⨁◯◯◯ |
Pancreatic cancer | 2 | 1028/248 909 | 1.12 (0.98 to 1.28) | 0.11 | 0%,<0.84 | 2 | 1028/248 909 | 1.004 (0.99 to 1.02) | 0.65 | 0%, 0.89 | ⨁◯◯◯ |
*⨁◯◯◯: very low; ⨁⨁◯◯: low; ⨁⨁⨁◯: moderate; ⨁⨁⨁⨁: high.
†A J-shaped association with the maximum risk reduction (17%) at 40 min/week.
‡A J-shaped association with the maximum risk reduction (18%) at 60 min/week.
§A J-shaped association with the maximum risk reduction (9%) at 30 min/week.
¶An L-shaped association with a large risk reduction up to 60 min/week.
CVD, cardiovascular diseases; GRADE, Grading of Recommendations Assessment, Development and Evaluation; RR, relative risk.